Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
Pharmacodynamics:Due to its adhesive and radiopaque properties when ingested envelops the mucous membrane of the gastrointestinal tract, providing a clear image of the gastrointestinal tract and microrelief of the mucosa on X-rays.
Pharmacokinetics:It is not absorbed from the gastrointestinal tract, the maximum contrast of the esophagus, stomach, duodenum - immediately after ingestion, the small intestine with anterograde filling - after 15-90 minutes, with retrograde - at once, distal parts of the small intestine and from the large intestine - depending from the position of the patient. Elimination through the gastrointestinal tract, complete elimination occurs in 24-48 hours.
Indications:Radiopaque examination of the gastrointestinal tract.
XXI.Z00-Z13.Z03 Medical surveillance and evaluation in case of suspected disease or pathological condition
Contraindications:Perforation of the gastrointestinal tract, obstruction of the large intestine, esophagotracheal fistulas, stenosis of the esophagus, violation of swallowing, constipation, malabsorption syndrome, operation on the organs of the gastrointestinal tract,gastrointestinal bleeding, hypersensitivity, food allergy, pregnancy.
Carefully:Bronchial asthma / allergic reactions, general severe condition of the patient after biopsy, colonic radiotherapy or fibrocolonoscopy, dehydration, ulcerative colitis exacerbation, gastrointestinal tract obstruction, acute diverticulitis, cystic fibrosis.
Pregnancy and lactation:Category Food and Drug Administration (US Food and Drug Administration) not determined. Adequate and well-controlled studies on humans and animals have not been conducted. An X-ray study of the abdominal organs during pregnancy is not recommended because of the risk of exposure to the fetus.
Dosing and Administration:Examination of the esophagus: 5-150 ml of 40-75% suspension of barium sulfate orally for examination at tight filling; 15-140 ml 40-85% suspension orally for double-contrast study.
Examination of the stomach or duodenum: 240-360 ml of 30-60% suspension of barium sulfate for the study with a hard filling orally; orally 75-140 ml of 80-85% suspension, followed by a double contrast test, and during the addition, another 150-300 ml of 30-50% suspension is additionally taken.
Study of the small intestine: 480-700 ml of 30-50% suspension of barium sulfate for study at tight filling; it is possible to introduce through the nasodeuodenal probe 500-2400 ml of 20-35% suspension; for retrograde examination of the small intestine - 2-2.5 l of 17% suspension rectally.
Retrograde examination of the large intestine: for research with tight filling - 1,5-2,5 l 15-30% of the suspension rectally; for study by the method of double contrasting - 350-1000 ml 50-65% rectally.
Computer tomography: 200-500 ml 1-2% orally or rectally.
Side effects:Constipation, appendicitis, abdominal pain, discomfort in the epigastric region, anaphylactic reactions, embolism, hypersensitivity, cramping abdominal pain, thickening of stool, diarrhea, perforation of the large intestine.
Overdose:Not described, symptomatic treatment.
Interaction:Not described.
Special instructions:To make a suspension of powder, it is mixed with boiled / distilled warm water; always add the powder to the water. Store the suspension at 15-30 ° C, shake before use.
To prevent the thickening of stool we recommend a plentiful drink.
Before the study, a slag-free diet and a laxative are recommended, the last meal is recommended to be done 20 hours before the test.
Barium sulfate is stored at a temperature of no more than 40 degrees Celsius.
Two cases of death of infants after inhaling powder have been described barium sulphate.